Urinary Citrate Is Associated with Kidney Outcomes in Early Polycystic Kidney Disease

Overview

Journal Kidney360

Specialty Nephrology

Date 2023 Jan 2

PMID 36591350

Authors

Daniel Ribeiro Rocha

Laixi Xue

Hiago Murilo Gomes Sousa

Ana Christina Carvalho Matos

Ewout J Hoorn

Mahdi Salih

Ita Pfeferman Heilberg

Affiliations

Soon will be listed here.

Abstract

Low urinary citrate and crystal deposition accelerated cystogenesis in an experimental model of polycystic kidney disease (PKD).Hypocitraturia, frequently observed in patients with autosomal dominant PKD (ADPKD) could contribute to disease progression.Present findings suggest lower urinary citrate in early PKD was associated with faster eGFR decline and worse kidney survival.

Citing Articles

A Urine pH-Ammonium Acid/Base Score and CKD Progression.

Svendsen S, Rousing A, Carlsen R, Khatir D, Jensen D, Hansen N J Am Soc Nephrol. 2024; 35(11):1533-1545.

PMID: 39485702 PMC: 11543018. DOI: 10.1681/ASN.0000000000000447.

Trigger Warning: How Modern Diet, Lifestyle, and Environment Pull the Trigger on Autosomal Dominant Polycystic Kidney Disease Progression.

Messing M, Torres J, Holznecht N, Weimbs T Nutrients. 2024; 16(19).

PMID: 39408247 PMC: 11479178. DOI: 10.3390/nu16193281.

The citrate transporter SLC13A5 as a therapeutic target for kidney disease: evidence from Mendelian randomization to inform drug development.

Gill D, Zagkos L, Gill R, Benzing T, Jordan J, Birkenfeld A BMC Med. 2023; 21(1):504.

PMID: 38110950 PMC: 10729503. DOI: 10.1186/s12916-023-03227-5.

A combination of β-hydroxybutyrate and citrate ameliorates disease progression in a rat model of polycystic kidney disease.

Torres J, Holznecht N, Asplund D, Amarlkhagva T, Kroes B, Rebello J Am J Physiol Renal Physiol. 2023; 326(3):F352-F368.

PMID: 38095025 PMC: 11207547. DOI: 10.1152/ajprenal.00205.2023.

Kidney phosphate wasting predicts poor outcome in polycystic kidney disease.

Xue L, Geurts F, Meijer E, de Borst M, Gansevoort R, Zietse R Nephrol Dial Transplant. 2023; 39(7):1105-1114.

PMID: 37985930 PMC: 11249971. DOI: 10.1093/ndt/gfad247.

References

Pei Y, Obaji J, Dupuis A, Paterson A, Magistroni R, Dicks E . Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol. 2008; 20(1):205-12. PMC: 2615723. DOI: 10.1681/ASN.2008050507. View

Akbari P, Nasri F, Deng S, Khowaja S, Lee S, Warnica W . Total Kidney Volume Measurements in ADPKD by 3D and Ellipsoid Ultrasound in Comparison with Magnetic Resonance Imaging. Clin J Am Soc Nephrol. 2022; 17(6):827-834. PMC: 9269662. DOI: 10.2215/CJN.14931121. View

Torres V, Keith D, Offord K, Kon S, Wilson D . Renal ammonia in autosomal dominant polycystic kidney disease. Kidney Int. 1994; 45(6):1745-53. DOI: 10.1038/ki.1994.227. View

Rowe I, Chiaravalli M, Mannella V, Ulisse V, Quilici G, Pema M . Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat Med. 2013; 19(4):488-93. PMC: 4944011. DOI: 10.1038/nm.3092. View

Blijdorp C, Severs D, Musterd-Bhaggoe U, Gansevoort R, Zietse R, Hoorn E . Serum bicarbonate is associated with kidney outcomes in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2020; 36(12):2248-2255. PMC: 8643593. DOI: 10.1093/ndt/gfaa283. View

Tanner G, Tanner J . Citrate therapy for polycystic kidney disease in rats. Kidney Int. 2000; 58(5):1859-69. DOI: 10.1111/j.1523-1755.2000.00357.x. View

Borrego Utiel F, Herrera Contreras I, Garcia E, Camacho Reina M, Moriana Dominguez C, Ocana Perez E . Urinary citrate as a marker of renal function in patients with autosomal dominant polycystic kidney disease. Int Urol Nephrol. 2021; 54(4):873-881. DOI: 10.1007/s11255-021-02953-0. View

Gianella F, Prado V, Poindexter J, Adams-Huet B, Li X, Miller R . Spot urinary citrate-to-creatinine ratio is a marker for acid-base status in chronic kidney disease. Kidney Int. 2020; 99(1):208-217. DOI: 10.1016/j.kint.2020.07.006. View

Holt C, Cowley D, Chalmers A . Rapid estimation of urinary citrate by use of a centrifugal analyzer. Clin Chem. 1985; 31(5):779-80. View

10.

Mao Z, Xie G, Ong A . Metabolic abnormalities in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2014; 30(2):197-203. DOI: 10.1093/ndt/gfu044. View

11.

Sargent J, Gotch F . Mass balance: a quantitative guide to clinical nutritional therapy. I. The predialysis patient with renal disease. J Am Diet Assoc. 1979; 75(5):547-51. View

12.

Frassetto L, Todd K, Morris Jr R, Sebastian A . Estimation of net endogenous noncarbonic acid production in humans from diet potassium and protein contents. Am J Clin Nutr. 1998; 68(3):576-83. DOI: 10.1093/ajcn/68.3.576. View

13.

Borrego Utiel F, Herrera Contreras I, Garcia E, Moriana Dominguez C, Ocana Perez E, Garcia Cortes M . Hypocitraturia is present when renal function is impaired in diverse nephropathies and is not related with serum bicarbonate levels. Int Urol Nephrol. 2021; 54(6):1261-1269. DOI: 10.1007/s11255-021-02992-7. View

14.

Torres V, Wilson D, Hattery R, Segura J . Renal stone disease in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1993; 22(4):513-9. DOI: 10.1016/s0272-6386(12)80922-x. View

15.

Nishiura J, Neves R, Eloi S, Cintra S, Ajzen S, Heilberg I . Evaluation of nephrolithiasis in autosomal dominant polycystic kidney disease patients. Clin J Am Soc Nephrol. 2009; 4(4):838-44. PMC: 2666433. DOI: 10.2215/CJN.03100608. View

16.

Ravine D, Gibson R, Walker R, Sheffield L, Kincaid-Smith P, Danks D . Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet. 1994; 343(8901):824-7. DOI: 10.1016/s0140-6736(94)92026-5. View

17.

Schrier R, McFann K, Johnson A . Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney Int. 2003; 63(2):678-85. DOI: 10.1046/j.1523-1755.2003.00776.x. View

18.

Torres J, Rezaei M, Broderick C, Lin L, Wang X, Hoppe B . Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney disease. J Clin Invest. 2019; 129(10):4506-4522. PMC: 6763267. DOI: 10.1172/JCI128503. View